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Introduction
Somatostatin is a small neuropeptide that is produced
in the central nervous system, where it acts as a
neurotransmitter. This neuropeptide also has an
important role in the neuroendocrine system as an
inhibitor of hormone release, the most striking
example of which is the inhibition of growth hormone
release. The role of somatostatin in eye disease
recently became of interest because of its role in
proliferative diabetic retinopathy and cystoid macular
oedema (1±3). In this paper, we discuss the role of
somatostatin in the retina and also present prelimin-
ary results of treatment of exudative age-related
macular disease with the somatostatin analogue,
octreotide.
Somatostatin in the retina
Somatostatin is found in the neuroretina of various
species, including humans. Immunoreactive and bio-
logically active somatostatin was first demonstrated in
the rat retina in the late 1970s (4±6) and was
subsequently found in other species (7, 8). It became
clear that somatostatin is locally produced in the
retina, because somatostatin immunoreactivity occurs
in extracts of frog and rat retinas, even 1 year after
transsection of the optic nerves. Pre-prosomatostatin
was produced in the retinas of all species studied, but a
differential expression of somatostatin-14 and somato-
statin-28 was observed (9). Loss of somatostatin
immunoreactivity was found after degeneration of the
ganglion cells (10). These results suggested somato-
statin production at the inner part of the retina. In all
species studied, somatostatin is located at the inner part
of the retina, although there are morphological
differences between species. Controversial findings
have been reported concerning somatostatin expression
in the outer nuclear layer (9). In general, somatostatin
has been localised in subclasses of amacrine cells
located at the proximal border of the inner nuclear
layer. These cells have processes entering the inner
plexiform layer (7, 11). We have demonstrated
somatostatin-14 mRNA in preparations of normal
human retinas ± an observation that contributes to
the opinion that somatostatin is synthesised in the
retina (Fig. 1).
Somatostatin receptors in the retina
The expression of somatostatin receptors (SSTs) has
been studied in various species. Autoradiographic
studies showed retinal SST expression in C57 black/
6J mice using somatostatin-14 and somatostatin-28
ligands (12). Specific binding of both ligands occurred
in three maxima: a broad band extending from the
retinal ganglion cells to the inner nuclear layers; a
narrow, inconstant band over the outer plexiform
layer; and a band over the retina pigment epithelium
and choroid. The most dense labelling occurred in a
broad band over the inner plexiform layer and inner
margin of the inner nuclear layer. Differential SST
expression was found with RT-PCR of the rat eye (13).
SST subtypes 2 and 4 were the major subtypes
expressed predominately in the rat iris/ciliary body
and retina respectively; SST1, SST3 and SST5 were
preferentially expressed in the posterior eye, including
the retina. Recently, we performed an immunohisto-
chemical study of human retinas, using a rabbit
polyclonal antiserum directed against SST1 and SST2A.
In this study we found SST1 expression by the retinal
ganglion cells, in the inner nuclear layer and retinal
pigment epithelium. SST2A expression was found in
the inner and outer nuclear and plexiform layers and
retinal pigment epithelium layer (RPE). The most
intensive staining was found in the inner plexiform
layer and inner nuclear layer. An example of SST2A
staining of the human retina is shown in Fig. 2. RT-
PCR of human retina preparations confirmed the
presence of somatostatin and SST2A mRNA and also
SST3 mRNA, but not SST4 and SST5 mRNA. These
results prove that these receptors are synthesised in
the human retina (Fig. 1). Until now, it has not been
possible to detect SST3 by immunohistochemistry. In
primary human retinal pigment epithelium cultures,
we found SST2A and somatostatin-14 mRNA expres-
sion ± an observation that suggests an autocrine
function for somatostatin-14 on the RPE (unpublished
observations).
Physiology of somatostatin in the retina
Until now, the exact role of somatostatin in the retina
has remained unresolved. Exogenous somatostatin,
when applied in solutions superfusing the retina, has
been shown to affect retinal responses to light.
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Nanomolar concentrations of somatostatin increased the
amplitude of extracellularly recorded massed oscillatory
potentials of the mudpuppy eyecup preparation. Electro-
retinograms showed an increased potential 1 min after
substitution, increasing to a maximum in 2±5 min (14).
Affected retinal ganglion cell responses were also found, by
a variety of methods, in rabbits and goldfish (15, 16). In
turtle retina, somatostatin excited extracellularly recorded
ganglion cells. The somatostatin content in the retina
increased during light exposure, whereas extended
exposure to dark revealed low concentrations of somato-
statin (17). This reduction may be related to an increased
release or a lower synthesis of somatostatin. A detailed
study of the role of somatostatin was reported by Zalutski &
Miller in 1990 (16). The results indicate that somatostatin
is a neuromodulator in the rabbit retina, producing long-
lasting changes in the signal-to-noise discharge pattern
and the centre±surround balance of ganglion cells. All
commonly encountered ganglion cell receptive fields were
affected by somatostatin in three different ways. The first
effect was a slow (seconds) excitation, occurring with a
threshold concentration of at least 100 nmol/l. The
second effect was an increase in signal-to-noise ratio,
because of a decrease in the spontaneous activity and a
concomitant increase in light-evoked spiking. The third
effect was a shift in centre±surround balance towards a
Figure 1 RT-PCR of whole human retina preparations. SST1,
SST2A, SST3 and somatostatin (SS)-14 are expressed.
Figure 2 Immunohistochemical staining
of the human retina. Top: SST2A (red) is
expressed by all cell layers of the
neuroretina, but extensively by the inner
plexiform layer. Bottom: The retinal
pigment epithelium express SST2A on
the apical side (arrow).
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more dominant centre. The last two observations were
evident in the nanomolar range, which is presumed to be
physiological because, in this range, somatostatin ana-
logues exert their inhibitory effect on hormone release.
Somatostatin and SSTs in retinal diseases
Cystoid macular oedema
Macular oedema, especially cystoid macular oedema
(CME) is a major complication of a variety of ocular
diseases. It is most frequently associated with uveitis,
retinal vascular disease (diabetic retinopathy, retinal
vein occlusion) and retinitis pigmentosa. Hereditary
dominant CME is also described, but the prevalence of
this disease is very low. CME often results in a decreased
visual acuity and this can be irreversible when the
oedema is long standing. Macular oedema is an
accumulation of fluid within the retinal tissue; it can
be seen on ophthalmoscopy and the severity can be
evaluated by fluorescein angiography.
Two systems with non-leaky tight junctions between
cells are essential for maintaining the fluid homeostasis
of the retina: retinal vascular endothelium (inner
blood±retinal barrier) and the retinal pigment epithe-
lium (outer blood±retinal barrier). Through these
barriers, some molecules such as oxygen pass directly,
but others such as albumin are unable to pass. CME
may result from a disruption of the inner blood±retinal
barrier, leading to an abnormal permeability of the
perifoveal retinal capillaries, or from a reduction of the
active transport of fluid out of the retina towards the
choroid. Dysfunction of the capillary endothelium, with
subsequent leakage from the capillaries surrounding
the macula may occur in response to inflammation,
ischaemia or toxic substances.
Dysfunction of the RPE layer is considered to be an
important pathogenic factor in ocular diseases associated
with CME. The RPE functions as a permeability barrier
between choriod and neurosensory retina by blocking the
inward migration of small molecules from the chorioca-
pillaris to the neurosensory retina and by active transport
of ions and fluid between retina and choriod. The RPE
creates an osmotic pressure gradient between retina and
choroid and, as consequence, neuroretinal apposition. As
fluid dissects into the nerve fibre layer, it may elevate the
inner limiting membrane and displace the nerve fibres to
create large accumulations of fluid. The macula becomes
thickened and cystic spaces containing a transudate are
present in the outer and inner plexiform layer and the
inner nuclear layer. The walls of these cystoid spaces are of
variable thickness and comprised of fibres (but are not true
walls). The macular region is the predilected site for the
accumulation of interstitial fluid because of its loose
packing of neural cells.
Permanent cystoid spaces may persist even after
treatment of the primary disease; moreover, a clinically
important complication of CME is irreversible loss of
visual acuity as a result of structural changes in the
retina. However, when the disease is treated in an early
stage and the vascular integrity is restored, the macula
may return to its normal function. No clear consensus
is yet available as to the treatment of cystoid macular
edema. The main approach is treatment of the under-
lying disease, such as immune suppression in auto-
immune uveitis. Treatment depends on the cause of the
disease and is often disappointing. Pharmacological
therapy for CME includes carbonic anhydrase inhibi-
tors, prostaglandin inhibitors and topical, periocular,
systemic steroids and more laser treatment (18).
Recently, we described the successful treatment of
CME with the somatostatin analogue, octreotide, in a
patient with dominant CME. In this patient the visual
acuity increased significantly after octreotide treat-
ment. Interruption of octreotide treatment resulted
subsequently in a decreased visual acuity (3). In
addition to dominant CME, we have treated 10 patients
with refractory CME secondary to uveitis with sub-
cutaneous octreotide or Sandostatin-LAR. We found
diminished macular oedema and improvement of the
visual acuity after octreotide treatment in 10 of 16 eyes
(RWAM Kuijpers et al. unpublished observations). In
four patients, it was also possible to taper immunosup-
pressive therapy, maybe because of an immune-
modulating effect of octreotide. During treatment, no
serious side effects were observed. The mechanism for
the observed improvement of visual acuity in these
patients is not clear. We have postulated four different
mechanisms through which SST may be involved (19):
1. Direct action of octreotide on the RPE. We found a high
expression of SST2A at the apical side of the RPE. Various
ion/water transport systems are located at this apical
membrane of the RPE adjacent to the subretinal space.
The action of octreotide in CME may be linked with these
ion transport systems, resulting in a rebalance of the fluid
and ion transport.
2. Somatostatin and its analogues have a suppressive effect
on the immune response (20). This may support the
effect of octreotide treatment in immune-mediated
disease such as autoimmune uveitis. A decrease in
disease activity in autoimmune uveitis may subsequently
diminish macular oedema.
3. Somatostatin binding sites were found on retinal
endothelium. Somatostatin has a direct antiproliferative
effect on retinal endothelium and SSTs are expressed on
activated blood vessels in inflammation (21, 22).
Suppression of activated endothelium may help to restore
the inner blood±retinal barrier.
4. Improvement of the neuroretinal function as discussed
above may contribute to an increase in visual acuity.
Somatostatin in retinal ischaemic disease
Vascular disease affecting the retina can be seen
directly on ophthalmoscopy. The signs of retinal
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vascular disease result from two changes of the retinal
circulation ± leakage and occlusion of the circulation.
Leakage results in haemorrhages, exudates and
oedema. Retinal vascular closure produces ischaemia
with liberation of vasoproliferative factors, which in
turn eventually produces neovascularisation. Ocular
neovascularisation and the associated haemorrhages
and fibrovascular proliferations are the underlying
threats to vision in diverse conditions such as diabetic
retinopathy, retinal vein occlusion, retinopathy of
prematurity, exudative age-related macular degenera-
tion, sickle cell retinopathy, radiation retinopathy, and
numerous others.
A possible role of growth hormone in the patho-
genesis of proliferative retinopathies was originally
suggested by the observation of regressing proliferative
diabetic retinopathy following infarction of the pitui-
tary after pregnancy (23, 24). This observation led to
Figure 3 Kaplan±Meier curve. The risk of vitreous haemorrhages was significantly reduced in patients with octreotide treatment
(P  0.0012). (Reproduced from (28) with permission.)
Table 1 Clinical features and SST2A staining in ischaemic retinal disease.
Patient Age (years) Sex History SST2A in (neo)vascular vessels
1 69 F Non-PDR Intraretinal (h) ++
2 67 M Non-PDR Intraretinal (h) +/2
3 55 F Early PDR Intraretinal (h) ++
4 78 F Early PDR Intraretinal (h) +/2
5 36 F Early PDR Intraretinal +/2 Preretinal 2
6 29 F Endstage PDR Preretinal ++
7 42 F Endstage PDR Preretinal +
8 60 F Endstage PDR Preretinal +/2
9 51 M Endstage PDR Intraretinal (h) +/2
10 32 M Endstage PDR Intraretinal 2 Preretinal +/2
11 74 M Endstage PDR Preretinal +/2
12 70 F Endstage PDR Intraretinal (h) +/2 Preretinal 2
13 60 M Early CRVO Intraretinal +
14 72 M Early CRVO Intraretinal (h) 2
15 90 F Early CRVO Intraretinal +
16 67 M Early CRVO Intraretinal (h) 2 Preretinal 2
17 83 F Early CRVO Intraretinal (h) +/2 Preretinal +/2
18 79 M Early CRVO Intraretinal (h) ++ Preretinal +/2
19 82 F Early CRVO Intraretinal (h) +/2 Preretinal +/2
20 47 M Endstage CRVO Intraretinal 2 Preretinal 2
21 74 F Endstage CRVO Intraretinal 2 Preretinal ++
22 68 M Endstage CRVO Intraretinal 2 Preretinal +/2
23 77 M Non-proliferative ischaemia Intraretinal 2
24 79 F Proliferative ischaemia Intraretinal 2
PDR, proliferative diabetic retinopathy; (h), hyalinised; CRVO, central retinal vein occlusion.
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the use of hypophysectomy as treatment for diabetic
retinopathy (25, 26); the introduction of laser photo-
coagulation led to the abandonment of this treatment.
Various studies have shown the successful treatment of
proliferative diabetic retinopathy with somatostatin
analogues (1, 2, 27). A cohort study of patients with
long-standing diabetes mellitus showed that the risk of
recurrent vitreous haemorrhages was significantly
reduced in all octreotide-treated patients; the Kaplan±
Meier curve (Fig. 3) shows the results after 2 years
follow-up (28). A significant difference persisted during
an observation period of 12 months.
In order to investigate the SST expression in vitro, 42
paraffin blocks of ischaemic retinas were retrieved from
eyes with diabetic retinopathy and ischaemic vascular
retinopathy. The eyes were enucleated because of
refractory pain and total loss of vision. Twelve
phthisical eyes, and eyes complicated by endophthal-
mitis were excluded. In the remaining 24 eyes, we
studied (by immunohistochemistry) the expression of
SST2A in non-proliferative n  3; early proliferative
n  11; and endstage proliferative n  10 stages of
ischaemic retinal disease, including diabetic retino-
pathy (12 eyes) and vascular occlusive disease (12
eyes). Sporadic expression was found in non-prolifera-
tive, and variable expression in early proliferative and
endstage proliferative ischaemic retinal disease. The
clinical and histological details are summarised in Table
1. Intraretinal neovascularisations stained generally
negative, whereas early preretinal neovascularisations
stained variably positive (Fig. 4). In endstage preretinal
vascularisations, variable but pronounced positive
staining was found in the preretinal membranes. In
areas of non-perfusion, the intraretinal ghost vessels
stained negative. These findings suggest that the anti-
angiogenic effects of somatostatin analogues may be
expected to be limited. However, we have to concede
that the material was highly selected and that the
sensitivity of staining in paraffin sections is less
sensitive than that in cryostat sections. Our observa-
tions are in concordance with the minimal effect of
somatostatin analogues on non-proliferative diabetic
retinopathy in clinical pilot studies (29, 30) and with
the more beneficial effect of somatostatin analogues on
advanced proliferative diabetic retinopathy after exten-
sive laser treatment (1, 2, 28).
Age-related macular degeneration
Age-related macular degeneration (ARMD) results in a
deterioration of the central retinal function, and is the
leading cause of legal blindness in people over 50 years
of age in Europe and the USA (31, 32). The clinical
aspects of ARMD were recently reviewed in an excellent
paper (33). Because the macula is in the central portion
of the retina, advanced ARMD often leads to irrever-
sible loss of social skills ± for example, the ability to
read. The precise pathogenesis of ARMD remains still
unclear. Two forms are distinguished: the atrophic form
and the neovascular, exudative form. The atrophic form
typically involves the choriocapillaris, RPE, and photo-
receptor elements (rods and cones) and does not involve
leakage of blood or serum; hence, it is called dry ARMD.
The neovascular, exudative form includes serous or
haemorrhagic detachment of RPE and choroidal
neovascularisation, which leads to leakage and sub-
sequent fibrovascular scarring of the macular area.
Loss of vision can occur in either form of the disorder.
The latter form is more aggressive, with choroidal
neovascularisation, and may progressively result in
blindness (34, 35). Among patients with severe loss of
visual acuity (,0.1 or worse), choroidal neovascular-
isation is the cause in at least 80% (36). Choroidal
neovascularisation can be identified before scarring
and extensive leakage cause irreversible loss of vision.
Leakage of blood or serum as a result of choroidal
neovascularisation may occur precipitously and is often
associated with the abrupt loss or distortion of vision.
The prevalence of ARMD increases dramatically with
age; in a population over 65 years old it is about 25%,
including 4% of patients with an exudative stage (31).
The therapeutic options are limited. Laser photocoagu-
lation, as performed in the Macular Photocoagulation
Study, is the only treatment for exudative ARMD that
Figure 4 Top: Intraretinal vessels usually stain SST2A-negative.
Bottom: Example of SST2A expression by a neovascular vessel in
the iris.
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has proven long-term benefit (37). Photodynamic
therapy is a non-thermal process leading to the
localised production of reactive oxygen species that
may mediate local cellular, vascular, and immunologi-
cal injury, and ultimately result in the partially selective
destruction of new blood vessels. Other, still experi-
mental, therapeutic treatment strategies such as radio-
therapy, submacular surgery, thalidomide, indocyanine
green-guided laser treatment, transplantation of RPE,
and retinal translocation are under investigation (33).
Recently, we have treated successfully 13 patients
(15 eyes) with exudative ARMD with octreotide
(Sandostatin-LAR) in dosage of 20 mg monthly. The
patient characteristics and results are summarised in
(Table 2). After 6 months, ten of the 15 eyes
maintained their vision and even an improvement of
visual acuity was observed. Two-year follow-up of these
initial treated eyes showed that the visual acuity
remained stable or deteriorated less than three lines
in 13 eyes and decreased more than 3 lines in two eyes
(Fig. 5). Patient 10 had to withdraw from treatment
because of an accident, the other patients were treated
for more than 2 years without significant side effects.
Although this was a non-controlled pilot study in a
diverse patient population, these results are very
promising for the long-term stabilisation of visual
acuity in patients with exudative macular degenera-
tion. This led us to initiate a prospective randomised
trial for the treatment of exudative macular degenera-
tion with octreotide.
In vitro investigation of human eyes with ARMD
showed SST2A expression in newly formed neovascular
vessels (38). An example of SST2A expression in sub-
RPE choroidal neovascular vessels is shown in Fig. 6.
We hypothesised that octreotide inhibited neovascular
endothelium proliferation directly or indirectly by
inhibition of insulin-like growth factor (IGF)-I. How-
ever, other possible action of octreotide are also of
interest ± such as restoration of RPE cell function,
which is believed to be affected in exudative ARMD.
Are the actions of somatostatin
analogues direct or mediated through
IGF-I in retinal disease?
Growth factors mediate intraocular angiogenesis in
ischaemic retinopathies. The potential impact of
identifying these mediators of retinal neovascularisa-
tion resulted in the investigation of a wide variety of
candidate molecules. The growth factor that best suits
such a paradigm is vascular endothelial growth factor
(VEGF). As already mentioned, a possible role for
growth hormone and IGF has been proposed. Growth
hormone stimulates the production of IGF-I in the liver
and subsequently increases its blood concentration.
Figure 5 Two-year results of the treatment of 13 patients (15 eyes)
with exudative macular degeneration with octreotide (Sandostatin-
LAR).
Table 2 Treatment of 13 patients (15 eyes) with exudative ARMD with octreotide (Sandostatin-LAR) for a period of 2 years.
Visual acuity
Eye Sex of patient ODS Age (years) Neovascularization Baseline 1 year 2 years
1 m OD 78 Occult 0.5 0.3 0.25
2 m OS 77 Mixed 0.3 0.4 0.3
3 f OS 70 Classic 0.8 0.7 0.4
4 m OD 71 Classic 0.01 0.05 0.05
5 f OD 69 Mixed 0.02 0.125 0.2
6 f OS 70 Occult 0.01 0.1 0.05
7 f OD 69 Mixed 0.1 0.2 0.125
8 OS Mixed 0.2 0.08 0.1
9 m OD 68 Occult 0.7 1.0 0.6
10 m OD 70 Occult 0.8 0.9
11 m OS 82 Occult 0.4 0.3 0.3
12 m OD 69 Occult 0.8 1.0 0.9
13 OS Classic 0.4 0.5 0.5
14 f OD 79 Occult 0.25 0.4 0.15
15 m OS 69 Mixed 0.5 0.1 0.08
OD, oculus dextra; OS, oculus sinistra.
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Somatostatin analogues are powerful inhibitors of
growth hormone release and therefore decrease the
blood IGF-I concentration. IGF-I causes neovascular-
isation in a rat cornea model, but intraocular
neovascularisation has not been demonstrated at
physiological concentrations (22). Correlation of
increased IGF-I concentrations with an increased
frequency of proliferative diabetic retinopathy is con-
troversial (39, 40). In mice treated with an SST2-
selective agonist, and in a transgenic growth hormone
antagonist mouse model, ischaemia-induced neovascu-
larisation was inhibited. In this model, neovascularisa-
tion could be stimulated after substitution of growth
hormone or IGF-I (41). Until recently, there was no
direct proof of a relationship between IGF-I and retinal
neovascularisation. Only recently it has been shown
that an IGF-I receptor antagonist suppresses retinal
neovascularisation in a mouse model of proliferative
retinopathy (42). VGEF is an essential hypoxia-induced
endothelial growth factor in proliferative retinopathy.
The IGF-I antagonist inhibits the action of VEGF
through inhibition of the second messenger, mitogen-
activated protein kinase. These results could also
explain the increase in diabetic retinopathy in patients
with poorly regulated diabetes. In these patients, a
partial resistance to growth hormone exists, resulting
in decreaed concentrations of IGF-I that prevent the
action of VGEF on the endothelium. After insulin
substitution, IGF-I concentrations increase, and subse-
quently the action of VEGF increases, resulting in an
increased neovascularisation (42).
Neovascularisation in ischaemic retinas from
patients with diabetes and patients with occlusive
vessel disease can express SST2A. Also, in retinas from
patients with exudative ARMD, SST2A is expressed by
neovascular choroidal vessels (38). The action of
somatostatin analogues in these diseases may be
mediated through IGF-I as discussed above, or by a
direct action of these analogues on neovascular
endothelium. However, other pathophysiological fac-
tors cannot be excluded. ARMD represents an exag-
geration of the ageing changes that takes place within
the RPE, photoreceptors and Bruch's membrane (43).
The initial event appears to stem from a failure of the
RPE to phagocytose spent photoreceptor membranes
correctly. This leads to thickening of Bruch's membrane
as basal laminar deposits and drusen. Finally, the RPE
and overlying photoreceptors undergo atrophy, and
closure of the underlying choriocapillaris occurs. The
exudative state develops when new choroidal vessels
penetrate Bruch's membrane, resulting in choroidal
neovascularisation. Functional changes in RPE may be
responsible for inappropriate transport and metabolism
of degradation products at the basis of this process.
SSTs are expressed by the RPE; moreover, somatostatin
is produced by the RPE, suggesting a role as an
autocrine factor. It is tempting to hypothesise that
somatostatin analogues contribute to the recovery of
RPE function in ARMD, in addition to exerting a direct
effect on neovascularisation and its indirect effect on
neovascularisation by decreasing the concentration of
IGF-I. The direct role of somatostatin analogues in
these retinal diseases, apart from inhibition of IGF-I,
remains to be explored.
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